Prof. David Paterson (Singapore)
Prof. Paterson directs ADVANCE-ID (ADVANcing Clinical Evidence for Infectious Diseases) at Saw Swee Hock School of Public Health. ADVANCE-ID is a clinical trials network comprising more than 40 hospitals across Asia. This network is jointly funded by the Wellcome Trust and a number of Singaporean institutions with an aim to conduct clinically important trials in the field of antimicrobial resistance (AMR). This comprises trials of antibiotics, diagnostics and prevention strategies. He is also an Honorary Professor at the University of Queensland and has more than 600 peer-reviewed publications predominantly in the area of AMR. His research focuses on the molecular and clinical epidemiology of infections with antibiotic-resistant organisms, with the intent of translating knowledge into optimal prevention and treatment of these infections. Multi-country clinical trials are the major component of his research portfolio, and the predominant focus of ADVANCE-ID.
Prof. Niels Høiby, FAAM, FESCMID (Denmark)
Prof. Niels Høiby is a Danish physician. He specialises in microbiology and was a pioneer in the study of biofilms and their role in conditions such as cystic fibrosis.
His research primarily focuses on chronic infections, taxonomy, clinical microbiology, hospital infections, antibiotic resistance mechanisms, and One Health infections.
Prof. Minggui Wang (Shanghai, China)
Prof. Minggui Wang serves as the Director of the Institute of Antibiotics at Huashan Hospital, Fudan University, where he holds positions as a Professor, Chief Physician, and Doctoral Supervisor. He is also the founding Chairman of the Chinese Society of Bacterial Infection and Resistance and a standing committee member of the Chinese Society of Infectious Diseases under the Chinese Medical Association. Additionally, he serves as the Deputy Director of the Infectious Diseases Society of China and holds various positions in national and international societies focusing on infection control and clinical microbiology, including the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society for Antimicrobial Chemotherapy (ISAC).
Prof. Wang has been recognized as a Leading Talent in Shanghai and honored as an Outstanding Academic Leader in the city. His research interests focus on the diagnosis and treatment of bacterial and fungal infections, as well as the rational use of antimicrobial agents. His research on drug-resistant microorganisms has received funding from prestigious sources such as the National Basic Research Program (973 Program), Major Programs of the National Natural Science Foundation of China, and the National Institutes of Health.
Dr. Zuoyu Xu (USA)
Zuoyu Xu, Ph.D., Program Officer, Bacteriology and Mycology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), USA (2007– present). Dr. Xu graduated from Fudan University, Shanghai, with his B.S. in Microbiology (1982), M.S. in Virology (1985), and subsequently became faculty at the Department of Biology, Fudan University (1985). Dr. Xu went to the United States in 1989, studied the function of molecular chaperones in regulating protein synthesis, and earned his Ph.D. degree in 1992. Dr. Xu conducted postdoctoral research in organelle inheritance and vesicle trafficking and joined the faculty at Dartmouth Medical School, Dartmouth College in 1997. Prior to working at the NIH, Dr. Xu was at the Centre for Research, Pfizer (1998-2007) where he led exploratory research on antimicrobial resistance and antibacterial drug discovery. At the NIH, Dr. Xu leads initiatives combating antimicrobial resistance, and directs new antibacterial discovery and development.
Prof. Jieming Qu (Shanghai, China)
Prof. Jieming Qu is a recognized Leading Talent in Shanghai and holds the positions of Party Secretary and Chairman of the Academic Committee at Ruijin Hospital, which is affiliated with Shanghai Jiao Tong University School of Medicine. He also serves as the Chairman of the Chinese Thoracic Society and Vice President of the Chinese Association of Chest Physicians.
Prof. Qu serves as the principal investigator of seven projects funded by the National Natural Science Foundation of China (including one key project) and one major national research project funded by the Ministry of Science and Technology of China, in addition to over ten other projects. He has received numerous awards, including the Shanghai Science and Technology Award (first prize), and the Ministry of Education’s National Science and Technology Progress Award and Shanghai Science and Technology Award (second prize).
He holds the position of Deputy Editor-in-Chief of the Chinese Journal of Tuberculosis and Respiratory Diseases, the Chinese Journal of Internal Medicine, and the Science Bulletin. Prof. Qu has published over 130 papers in prestigious international journals such as Cell, The Lancet, BMJ, Cell Research, Journal of Clinical Investigation, and the European Respiratory Journal, with a total impact factor exceeding 1200 and a total citation count of over 20,000. He has also served as the Editor or Deputy Editor of 10 monographs, including the English-language book COVID-19: The Essentials of Prevention and Treatment.
Prof. Visanu Thamlikitkul (Thailand)
Prof. Visanu Thamlikitkul is infectious disease physician by training. He received his medical degree from the Faculty of Medicine Siriraj Hospital, Mahidol University and a certificate of clinical fellowship in infectious diseases from University of Cincinnati, USA. He also holds a Master Degree in Clinical Epidemiology from McMaster University, Canada. He is the former head of Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University. He is also the leader of Thailand Antimicrobial Resistance (AMR) program and the director of WHO Collaborating Centre for AMR Prevention and Containment at Faculty of Medicine Siriraj Hospital in Thailand.
Prof. Juan Pablo Horcajada (Spain)
Head of the Department of Infectious Diseases and Coordinator of Infectious Diseases Research at Hospital del Mar, Barcelona, Spain. Professor of Medicine and Vice-Dean of Medicine at Pompeu Fabra University, Barcelona. His research focuses on optimizing antibiotic use, applying PK/PD principles, and conducting trials and clinical studies for the treatment of infections caused by multidrug-resistant bacteria, especially Pseudomonas aeruginosa. He has authored over 320 scientific articles (H-index 60) and has overseen numerous competitive research projects and doctoral theses. He participates in several international clinical trials with antimicrobials. Delegate in Spain and Member of the Steering Committee of the European Committee for Infection Control (EUCIC) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).
Prof. Baiyi Chen (Shenyang, China)
Prof. Baiyi Chen is a Professor, Chief Physician, and Doctoral Supervisor in the Department of Infectious Diseases at the First Hospital of China Medical University. He is a Director of the Global Chinese Association of Clinical Microbiology and Infectious Diseases (GCACMID) and serves as Deputy Director of the Infectious Diseases Society of China. Additionally, he holds deputy director and standing committee member roles in various national committees on infection control and clinical microbiology.
Professor Chen has made significant contributions to the field of infectious diseases, specializing in the etiological diagnosis of fever of unknown origin (FUO) and the diagnosis and treatment of complex bacterial and fungal infections in various organs and systems. He is also an expert in the diagnosis and treatment of drug-resistant bacterial infections and opportunistic infections in immunodeficient populations.
His research interests include the pathogenesis of infectious diseases and the prevention, diagnosis, and treatment of antimicrobial-resistant bacteria. He has led nine projects, including those funded by the National Natural Science Foundation of China, and has published over 120 papers.
Prof. Qing Cao (Shanghai, China)
Prof. Qing Cao, MD, is a Chief Physician and Master Supervisor at the National Children’s Medical Center, affiliated with Shanghai Jiao Tong University School of Medicine. She holds several key positions, including Director of the Internal Medicine Department, Director of the Infectious Disease Department, Director of the Pediatric Standardized Medical Residency Training Base, and Director of the Infection and Immunology Center. Additionally, she serves as the Deputy Director of the Infection Research Laboratory at the Pediatric Translational Medicine Institute.
Prof. Cao is an active member of several professional societies. She is the Deputy Director of the Infectious Diseases and Chemotherapy Branch of the Shanghai Medical Association, Deputy Leader of the Pediatric Group of the Shanghai Medical Association’s Infectious Diseases Branch, and Secretary of the Shanghai Medical Association’s Pediatric Branch. She also serves on the Committee for Clinical Application and Management of Antimicrobial Agents in Shanghai and has served as a reviewer for journals such as the Chinese Journal of Pediatrics and Pediatrics & Neonatology.
Her main research interests include pathogenic bacteria and host immune mechanism, anti-infection treatment of sepsis based on gene drug genomics and blood drug concentration monitoring, the mechanism of action of bacteriocin on intestinal endogenous infection, the clinical application of children’s fecal bacteria transplantation, and vaccine inoculation evaluation in special populations.
A/Prof. Andrea Kwa Lay Hoon (Singapore)
A/Prof. Andrea Kwa received a B.Sc. (Pharm) from the National University of Singapore, Singapore in 1996, and her Doctor of Pharmacy Degree from the Albany College of Pharmacy, New York, USA, in 2006. She also attained Added Qualifications in Infectious Diseases in Pharmacotherapy from the Board of Pharmacy Specialties, USA, since 2007. She has finished her postdoctoral research fellowship of 2 years in anti-fungal resistance and molecular diagnostics with University of Pittsburgh, School of Medicine, Division of Transplant Infectious Diseases. She is a Deputy Director (Research & Innovation) in SGH, and Associate Professor with Emerging Infectious Diseases Program, Duke-National University of Singapore.
A/Prof. Gauri Rao (USA)
A/Prof. Gauri Rao is an Associate Professor at the University of Southern California and the Director for the Center for Quantitative Drug and Disease Modeling. A/Prof. Rao earned her PharmD from the University of Buffalo. She completed her postdoctoral training in Infectious diseases Pharmacokinetics/Pharmacodynamics (PK/PD) with a Masters in Pharmacometrics at the University at Buffalo in collaboration with Hoffmann La Roche.
Her translational research program focuses on using a systems-based approach to study the dynamic interplay between host immune response, antibiotic treatment, and bacterial resistance mechanisms to determine its impact on disease progression and biomarker response. She has applied innovative quantitative approaches for designing optimized antibiotic as well as phage treatment regimens.
A/Prof. Rao’s innovative work focused on addressing antimicrobial resistance has been supported by National Institutes of Health (NIH), Department of Defense (DOD), Food and Drug Administration (FDA) and Cystic Fibrosis Foundation (CFF). A/Prof. Rao is the 2023 Leon I. Goldberg Early Investigator Award recipient, which recognizes and honors young scientists for outstanding accomplishments in the field of clinical pharmacology achieved early in their careers.
A/Prof. Cornelia Landersdorfer (Australia)
A/Prof. Cornelia Landersdorfer, PhD, is an Associate Professor at the Monash Institute of Pharmaceutical Sciences, Monash University. She leads a research group that integrates dynamic in vitro infection experiments with molecular studies and mechanism-based mathematical modelling to optimise dosing of antibiotics against critical Gram-negative pathogens. Her group also designs and analyses population pharmacokinetic/pharmacodynamic studies for antibiotics and other drugs. Her research has generated new knowledge on the pharmacokinetics of polymyxins in different patient groups, as well as their pharmacokinetics/pharmacodynamics in in vitro and in vivo studies. She has >140 peer-reviewed publications, and was awarded the Georgina Sweet Award for Women in Quantitative Biomedical Sciences in 2018. A/Prof Landersdorfer is Academic Deputy Director of the Monash-Moderna Quantitative Pharmacology Accelerator. Her research is supported by NHMRC, ARC, NIH and pharmaceutical industry, and has informed dosing guidelines and patient therapy internationally.
Prof. Miao Yan (Changsha, China)
Dr. Sonia Luque Pardos (Spain)
Dr. Sònia Luque Pardos, Pharm D., Ph.D., obtained her degree at the University of Barcelona and her Ph.D. from the University Autònoma of Barcelona. She is a faculty member of the Pharmacy Department at the Hospital del Mar, Barcelona, Spain.
She has a Master’s Degree in Application and Control of Antimicrobial Therapy of Universitat Autónoma of Barcelona. She has been working in the study of the pharmacokinetic and pharmacodynamics of antimicrobials and she is currently involved in various national and international research projects. She is a member of the Infectious Pathology and Antimicrobials Research Group (IPAR). Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), of the Spanish Network for Research in Infectious Diseases (REIPI). Nowadays, she is part of the Executive Committee of Pharmacokinetics/Pharmacodynamics (PK/PD) of Anti-Infectives Study Group (EPASG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). She was awarded a postdoctoral fellowship at the Center for Pharmacodynamics of the University of Liverpool. She has published over 50 articles in the field of the Infectious Diseases in different international journals.
Dr. Xiaofang Wang (Australia)
Dr. Xiaofang Wang received her PhD in medicine from the University of Melbourne and her master’s degree in Biostatistics at Monash University. She is currently employed as a Biostatistician at the Clinical Epidemiology and Biostatistics Unit (CEBU) of the Murdoch Children’s Research Institute (MCRI). In her role at CEBU, she develops her skills in design and analysis of clinical trials, with a particular interest in innovative trial methodologies such as adaptive, multi-arm and platform trials.
Dr. Sean Ong (Australia)
Dr. Sean Ong is an infectious diseases physician from Singapore who is currently pursuing a joint PhD programme at the University of Toronto and University of Melbourne. His thesis research focuses on approaches toward optimizing the design and delivery of clinical trials in bloodstream infections, through novel outcome development, application of causal inference statistical methods, and innovations in informed consent. He has significant experience in clinical trials and is part of the BALANCE and SNAP international trial networks, two of the largest clinical trial networks studying bloodstream infections to date.
Prof. Yang Wang (Beijing, China)
Dr. Ilias Karaiskos (Greece)
Dr. Ilias Karaiskos is an accomplished professional in the field of Internal Medicine and Infectious Diseases. He completed his Internal Medicine training in 2010 at the University Hospital Attikon in Athens, Greece, followed by a fellowship in Infectious Diseases at University Hospital Laikon, Athens, Greece. He achieved his PhD on the topic of ‘Pharmacokinetic of CMS and the application of a loading dose of CMS’, under the guidance of Professor Helen Giamarellou in 2014. His dedication in research were recognized with the Best PhD Award from the Hellenic Society, along with numerous awards in Greek congresses. He is currently employed as an Infectious Diseases at Hygeia General Hospital and is a member of the research group ‘the Critically Ill Study Group of ESCMID” and “ESCMID PK/PD of Anti-Infectives Study Group”. With a wealth of experience in critical care medicine, antimicrobial stewardship, and combating antimicrobial resistance, he possesses profound expertise in managing hospital and community-acquired infections, particularly focusing on multidrug resistance and prostatitis. Dr. Karaiskos stands out as a leader in the hospital and healthcare industry, demonstrating unparalleled skills and dedication to advancing infectious disease management.
Prof. Tony Velkov (Australia)
Prof. Velkov is a world leader in antibiotics and drug discovery, having made significant contributions to the commercialisation of novel antibiotics and building Australia’s international reputation in the antimicrobial field. The significant translational impact of his innovative research is demonstrated by his successful programs centred on the development of novel antibiotics from concept to clinical trials, which represents a major socioeconomic achievement for an Australian academic research group.
A/Prof. Xukai Jiang (Qingdao, China)
Dr. Jiang obtained his PhD from the State Key Laboratory of Microbial Technology, Shandong University, China. Since 2018, he has been a research fellow in Li Lab at Monash University, Clayton Campus. His research is multi-disciplinary and integrates computational biology, bioinformatics, biophysics and pharmacology. His interests include structure of biological membranes, lipid phase separation, membrane-drug interaction, regulatory mechanism of membrane protein, and AI-driven drug design. He has published 39 articles (19 as first, co-first or corresponding author) in major international journals, including Nat. Commun., J. Med. Chem., Chem. Sci., Adv. Sci., and J. Biol. Chem.
Prof. Guo-Bao Tian (Guangzhou, China)
Prof. Guobao Tian is a Professor and Doctoral Supervisor at Sun Yat-sen University. He is an esteemed recipient of the National Natural Science Fund of China for Distinguished Young Scholars. Additionally, he has been honored with the Natural Science Fund of Guangdong Province for Distinguished Young Scholars and recognized as a Guangdong Special Support Plan Young Top-Notch Talent. At Sun Yat-sen University, he serves as the Deputy Director of the Academic Committee of the School of Medicine, Vice President of the School of Medicine, and Deputy Director of the Medical Education Department. Moreover, he is a member of the fourth group aiding Tibet, appointed by the Organization Department of the Central Committee of the CPC.
Professor Tian’s research focuses on antimicrobial resistance and biosafety. He has published over 60 SCI papers in top-tier international journals such as The Lancet Infectious Diseases and Lancet Microbe. He has led more than ten projects, including key and major international collaborations under the National Natural Science Foundation of China. Additionally, he has led and participated in over ten National Science and Technology Major Projects on infectious diseases and National Key Research and Development Programs of China. As a first inventor, he has filed 11 patents, with 5 granted, and has contributed to 5 monographs. Furthermore, he serves as an expert reviewer for significant projects under the National Natural Science Foundation of China, major international collaborations, and youth and regional projects, as well as for conferences.
Dr. Yu-Wei Lin (Australia)
Dr. Yu-Wei Lin is a passionate clinical researcher/pharmacometrician whose long-term career goal is to make pioneering break-through discoveries in the treatment of life-threatening infections caused by pandrug-resistant Gram-negative pathogens. Yu-Wei holds a PhD in PharmSci from the University of Sydney and a double degree in PharmD (first class honours) and PharmSci from the University of South Australia. Yu-Wei has published 50+ publications to date and has presented his research both nationally and internationally at various conferences, including the AAPS Conference (2017). Yu-Wei was a finalist in the Monash Industry Pitch Competition (2018), a recipient of the Ted Martonen Research Award (2017), AAPS Graduate Student Award in PK/PD, and Clinical Pharmacology and Translational Research (2017), Royal Society of NSW Graduate Student Award (2017), ISAM Best Oral Presentation Award (2017), Lion Club Research Awards (2018-2019), Monash Bridging Fellowship Award (2018) and ASCEPT Young Investigator Award (2019). His research is well-funded, having received over AUD 1.5 million from international agencies such as the US NIH and the Australian NHMRC. Dr. Lin has garnered industry experience in model-informed drug discovery and development (MIDD) and currently serves as the Director of Pharmacometrics at Certara. Over the past two years, he has contributed to more than 50 MID3 projects across various disease areas.
A/Prof. Yinggang Zhu (Shanghai, China)
A/Prof. Zhu is a Deputy Chief Physician in the Department of Pulmonary and Critical Care Medicine and serves as Head of the Fever Clinic at Huadong Hospital. He is the secretary of the Infectious Disease Group of the Respiratory Medicine Branch of the Chinese Medical Association and a member of the Infection Specialty Committee (IDSC) of the Chinese Medical Education Association, as well as the Critical Care Medicine Working Committee of the Respiratory Physicians Branch of the Chinese Medical Doctor Association (CACP). Additionally, he also collaborates with the European Collaborative Expert Group on Aerosolized Antibiotic Treatment for Ventilator-Associated Pneumonia (ENAVAP).
A/Prof. Zhu has devoted his research to the role and mechanism of mesenchymal stromal cells (MSCs) and their derivatives in treating acute lung injury. His notable work, published in Stem Cells in 2014, has been cited over 700 times and was recognized as one of the top 5 most cited articles in Stem Cells magazine that year. In 2017, he received an international trainee scholarship from the American Thoracic Society, and in 2022, he was honored as the Wiley China Open Science Scholar of the Year.
A/Prof. Qi (Tony) Zhou (USA)
A/Prof. Zhou is a recognized expert in pharmaceutical solids and inhalation dosage forms. He is an Editor of AAPS PharmSciTech and Editorial Board Member of 9 pharmaceutical journals including International Journal of Pharmaceutics, Pharmaceutical Research and Journal of Pharmaceutical Sciences. He has published more than 110 journal articles, and filed 9 patents/applications. Dr. Zhou’s research has attracted more than $11 million funding including NIH R01 grants and many industrial projects. Dr. Zhou’s significant contribution to the field of pharmaceutical science has been recognized by many prestigious awards including 2021 AAPS Emerging Leader Award, 2019 DDL Emerging Scientist Award from The Aerosol Society, 2018 Rising Star Scholarship Award from National Institute for Pharmaceutical Technology & Education (NIPTE), 2017 New Investigator Award from International Society of Aerosols in Medicines (ISAM), and 2016 Emerging Researcher Award from International Pharmaceutical Excipients Council of the Americas Foundation (IPEC).
A/Prof. Yiyun Liu (Guangzhou, China)
A/Prof. Yiyun Liu, Ph.D, is an Associate Professor at the College of Veterinary Medicine, South China Agriculture University. Her research focuses on the mechanisms of antibiotic resistance and strategies for controlling resistance. She has published more than 20 papers in esteemed peer-reviewed journals, including Lancet Infectious Diseases (twice), Trends in Microbiology, and Food Research International. Her published papers have been cited over 4000 times, with one paper recommended by F1000 prime (now Faculty Opinions).
Dr. Meiling Han (Australia)
Dr. Meiling Han is a group leader and an Australian Research Council (ARC) DECRA fellow at Monash Biomedicine Discovery Institute, Monash University. She earned her PhD in pharmacology and pharmaceutical science from the Monash Institute of Pharmaceutical Science in 2018. Dr. Han’s research focuses on addressing the urgent issue of antimicrobial resistance, a significant threat to global public health. Currently, she leads an independent research team dedicated to unravelling the mechanisms by which bacteria adapt to attain antibiotic resistance. Her goal is to identify new drug targets for the development of much-needed novel antimicrobial therapeutics.
Dr. Han’s research has yielded significant achievements, with 56 peer-reviewed publications in prestigious journals such as Nature Communication, Nature Microbiology, Cell Reports, and Advanced Science. She has secured numerous research grants totaling over $2 million, including ARC Discovery Early Career Research Awards, NHMRC Ideas Grants, and the Rod Rickard Fellowship from Australian Academy of Science.
Dr. Nusaibah Abdul Rahim (Malaysia)
Prof. Yan Zhu (Tianjin, China)
Dr. Zhu received PhD in Microbiology (2013) from University of Chinese Academy of Sciences. He then joined the University of Queensland and worked on food microbiology. In 2015, He joined Monash University and worked on systems pharmacology. In 2022, he took a full-time Professor position at Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences and works on systems biology. His research is well funded by Tianjing Synthetic Biotechnology Innovation Capacity Improvement Project (2022-2025), CAS Pioneer Initiative Action (2024-2026), National Key Research and Development Program of China (2023-2028), CAS Progress of Strategy Priority Research Program C (2024-2026).
He has published two book chapters, and 91 peer-reviewed papers thus far. His recent first-authored research paper on polymyxin-dependence was featured on the front cover of Advanced Science in 2020. The novel synthetic lipopeptide antibiotic paper published on Nature Communications 2022 was selected as Editorials’ Highlights. He serves as a member of Technical Committee of Computational Synthetic biology, Chinese Bioinformatics Society, and an Associate Editor of International Journal of Antimicrobial Agents, Gene Reports, SynBio, and Synthetic Biology and Engineering.
Prof. Jianhua Liu (Guangzhou, China)
Prof. Jianhua Liu is a Professor at the College of Veterinary Medicine, South China Agricultural University. A recipient of the National Science Fund for Distinguished Young Scholars, She is a member of National Expert Committee for Control of Veterinary Drug Residue and Antimicrobial Resistance. She also serves on the editorial boards of Applied and Environmental Microbiology, One Health Advances, and Zoological Research, and is an associate editor of Frontiers Microbiology.
Her current research focuses on the emergence and transfer mechanisms of antimicrobial resistance in Enterobacteriaceae, as well as the evolution of antimicrobial resistance and resistance plasmids. She was the first to discover the emergence of plasmid-mediated colistin resistance gene mcr-1 and transferable RND-type efflux pump gene cluster tmexCD1-toprJ1. Prof. Liu has published over 70 research articles in the top journal in the field of antimicrobial resistance, including The Lancet Infectious Diseases, Nucleic Acids Research, mBio, Journal of Hazardous Materials, Emerging Infectious Diseases, and Clinical Microbiology and Infection. Her published papers have been cited more than 6000 times, with three being recommended by F1000 prime (now Faculty Opinions).
Prof. Hui Wang (Beijing, China)
Prof. Hui Wang is a Professor and Director of the Department of Clinical Laboratory at Peking University People’s Hospital. She is a recipient of the National Science Fund for Distinguished Young Scholars Award, a Newton Advanced Fellow, and recognized as a National Health and Wellness Outstanding Young Expert. Additionally, she serves as the Director of the Department of Laboratory Medicine at Peking University Health Science Center and as the Chairman of the Clinical Microbiology Branch of the China Medical Promotion Association.
Prof. Wang has a long-standing interest in elucidating the molecular epidemiology and drug resistance mechanisms of drug-resistant bacteria, and dynamically tracking the epidemiology, population structure characteristics, and microevolution mechanisms of clinically important drug-resistant bacteria in China. In the past five years, she has published 71 SCI papers as the first or corresponding author in top journals such as Nature Communications, Clinical Infectious Diseases, Genome Medicine, and Drug Resistance Updates. Five of her papers have been selected for the top 1% of ESI highly cited papers.
Prof. Wang has participated in formulating 3 international standards, presided over the formulation of 3 industry standards, and hosted the development of 12 guidelines and consensus documents. She has received awards such as the National Science and Technology Progress Award and the Chinese Medical Science and Technology Progress Award.
A/Prof. Xiaofen Liu (Shanghai, China)
Dr. Dandan Yin (Shanghai, China)
Dr. Dandan Yin is an Assistant Researcher at the Institute of Antibiotics, Huashan Hospital, Fudan University. Her research focuses on in vitro antimicrobial susceptibility testing and mechanisms of antimicrobial resistance in bacteria. A member of the Youth Commission of the China Antimicrobial Resistance Surveillance System (CARSS), her work is funded by the National Natural Science Foundation of China. She has published over 15 related articles.
Prof. Qiwen Yang (Beijing, China)
Prof. Qiwen Yang, a Doctoral Supervisor, is recognized as a Leading Talent in Technological Innovation within the Ten-Thousands Talents Program. He currently serves as the Deputy Director of the Clinical Laboratory at Peking Union Medical College Hospital.
Prof. Yang holds the position of Chairman of the Chinese Committee on Antimicrobial Susceptibility Testing (ChiCAST). Additionally, he serves as the Deputy Director of the Expert Committee of the National Health Commission on Antimicrobial Susceptibility Testing and Standard Research (ECAST) and is the Secretary-General and Deputy Director of the Clinical Microbiology Laboratory Specialized Committee of the Chinese Hospital Association. He has led over 70 national projects, including those funded by the National Natural Science Foundation of China and the National Key Research and Development Program of China. Prof. Yang has published more than 180 papers in domestic and international journals, with over 70 papers as the first or corresponding author in journals indexed in SCI, including Lancet Microbe, Clinical Infectious Diseases, Emerging Microbes & Infections, and Clinical Chemistry. He holds 25 patents as the first inventor, with many of his innovations widely used in clinical practice.
Prof. Yang has received numerous awards, including the Beijing Science and Technology Award (first prize), the Science and Technology Improvement Award in Higher Institutions (second prize), and the Science and Technology Improvement Award from the Chinese Preventive Medicine Association (second prize).
Dr. Xingchen Bian (Shanghai, China)
Dr. Xingchen Bian specializes in antimicrobial pharmacology, clinical pharmacology, and pharmacometrics. Her research focuses on using in vitro pharmacokinetic/pharmacodynamic and omics technologies to explore the effects of polymyxin combination therapy, with particular emphasis on the synergistic mechanisms related to cell membranes. Utilizing her experience in early-phase clinical trials for innovative antimicrobials, Dr. Bian actively employs model-informed drug development strategies to support the research and development of new pharmaceuticals.
Dr. Wanzhen Li (Shanghai, China)
Dr. Wanzhen Li is a fellow at Institute of Antibiotics, Huashan Hospital of Fudan University (Shanghai). She completed her PhD in Internal medicine (Infectious disease) at Huashan Hospital of Fudan University in 2022. Dr Li’s research has been focused on the anti-bacterial infections, including PK/PD studies of antimicrobial agents, and bacterial cell-cell and bacteria-host interactions. Over the past 4 years, she participated in the National Natural Science Foundation, National Major Scientific and Technological Special Project for “Significant New Drugs Development” during the 13th Five-year Plan Period, Shanghai Talent Awards, and presided over a project of Shanghai Municipal Health Commission. She has published 3 SCI papers as first author.
A/Prof. Xiaohua Qin (Shanghai, China)
A/Prof. Xiaohua Qin, Doctor of Medicine, is an Associate Chief Physician and Master’s Supervisor at the Institute of Antibiotics, Huashan Hospital, Fudan University, where she also serves as the Assistant to the Director and Academic Secretary. A/Prof. Qin is a Youth Committee Member of the Infectious Diseases Society of China and a Member of the first session of the Society of Emergency and Security of Pharmaceuticals of the Shanghai Medical Doctor Association. Additionally, she is the Secretary of the Microbial Infection and Antimicrobial Resistance Therapy Committee of the Shanghai Medical Association. Dr. Qin’s expertise lies in the diagnosis and treatment of infectious diseases, with a particular focus on bacterial resistance mechanisms. She has led and completed projects funded by the National Natural Science Foundation, and participated in several key projects funded by the Ministry of Science and Technology. Dr. Qin has published 16 SCI papers and 8 core journal papers.
A/Prof. Xiaojie Wu (Shanghai, China)
A/Prof. Xiaojie Wu is the Deputy Director of Clinical Pharmacology Research Center at Huashan Hospital affiliated with Fudan University. She holds significant roles in various academic and professional societies, including Deputy Chairman of the Oncology Clinical Research Training Base of the China Medical Education Association and Vice Chairman of the Youth Committee of the Drug Clinical Trial professional Committee of the Chinese Pharmacological Society. She is also an active member of several other pharmacological committees and workgroups, including DIA Clinical Pharmacology Community.
A/Prof.. Wu is a distinguished researcher specializing in early clinical studies of innovative drugs and clinical pharmacology. She has participated in over 170 phase I clinical trials and has led or co-led more than 30 phase I and II trials. A/Prof.. Wu has extensive experience in clinical trial design and protocol development. She has been a visiting scholar at the Royal Danish Hospital and completed the Harvard Global Clinical Scholars Research Training (GCSRT) program. In 2015, she was seconded to the NMPA Drug Evaluation Center and Human Genetic Resources Management Office, and she worked as a part-time reviewer of the General Department of NMPA Drug Evaluation Center. She also worked on human genetic resource management with the Ministry of Science and Technology in 2019.
She has published over 60 research papers, with 15 as first or corresponding author in the past five years, including 13 indexed by SCI. A/Prof. Wu has contributed as editor and deputy editor to 2 key textbook, Pharmacokinetics and Pharmacodynamics: Concepts and Applications, and Drug Clinical Research Theory and Practice. A/Prof. Wu holds grants from Shanghai Science and Technology Committee. She has been main contributor major projects of the 13th Five-Year Plan and key research and development plans of the Ministry of Science and Technology. She has received numerous awards, including the Second Prize of the Chinese Pharmaceutical Association Science and Technology Award (2023).
A/Prof. Jianzhong Ye (Wenzhou, China)
Jianzhong Ye is an Associate Professor in the Department of Clinical Laboratory at the First Affiliated Hospital of Wenzhou Medical University and Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province. Since December 2021, he has also served as an attending physician. A/Prof. Ye completed his M.D. in Clinical Medicine at Zhejiang University under the mentorship of Prof. Lanjuan Li, and obtained his Master’s degree in Clinical Laboratory Diagnosis from Wenzhou Medical University, guided by Prof. Tieli Zhou. His research focuses on antimicrobial resistance, particularly in carbapenem-resistant bacteria. A/Prof. Ye has secured several grants, including projects funded by the National Natural Science Foundation of China. He has published extensively in high-impact journals, making significant contributions to the field of clinical microbiology.
Dr. Jinxin Zhao (Australia)
Dr. Jinxin Zhao is a Team leader of Bioinformatics and Computational Biology in the Laboratory of Antimicrobial Systems Pharmacology at Monash Biomedicine Discovery Institute. His research interests focus on developing novel efficacious therapies against life-threatening Gram-negative ‘superbug’ by using microbial evolution, systems pharmacology, and computational modelling. He completed his PhD in antimicrobial systems pharmacology from Monash University in 2021. He secured numerous grants and awards such as the DAAD short-term research Fellowship from the DAAD German Academic Exchange Service, the Australia-Germany Joint Research Grant and multiple travel awards. His roles include significant editorial responsibilities, being an editor for Journal of Global Antimicrobial Resistance and junior editors for iMeta, Asian Journal of Pharmaceutical Sciences and Genomics, Proteomics & Bioinformatics. In addition to academic research roles, he is also an executive committee member of the ISAC, the chair of ISAC Early Career, the American Society for Microbiology Young Ambassador to Australia and the AMR Insights Ambassador.
A/Prof. Zhijun Song (Denmark)
A/Prof. Zhijun Song, clinical microbiologist at University Hospital of Southern Denmark, Esbjerg, Denmark. Educated at Guangxi Medical University as a doctor, achieved Ph.D. at University of Copenhagen, Denmark, postdoctoral of Florida International University. Major interest: diagnosis and treatment of bacterial biofilm infections. More than 100 publications. Ph.D. Supervisor.
Prof. Xiaoping Huang (Suzhou, China)
Dr. Dongdong Zhao (Hangzhou, China)
Dr. Dongdong Zhao, MD, is a Chief Physician in the Department of Liver Infection at Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine, as also serves as a Master’s Supervisor at Zhejiang University.
Dr. Zhao serves as a committee member of the Committee on Tropical Diseases and Parasitic Diseases of the Zhejiang Society of Integrative Medicine. Additionally, he is a member of the Clinical Epidemiology and Evidence-Based Medicine Branch of the Zhejiang Medical Association. His research interests lie in the diagnosis and treatment of multidrug-resistant bacterial infection and the rational use of antimicrobial agents. He has published over 30 papers indexed in SCI. Dr. Zhao has led two projects funded by the National Natural Science Foundation of China and one project funded by the Chinese Medical Association. He is also a key member in a project funded by the National Key Research and Development Program of China.
Dr. Luisa Sorlí Redó (Spain)
Dr. Luisa Sorlí worked as an Infectious Diseases Physician at the Hospital del Mar in Barcelona.
At this time, Dr. Luisa Sorlí is working in the Post-Surgical Medical Care Unit and Hematologist Service as a consultant. The treatment of multidrug-resistant Gram-negative bacilli infections and the pharmacokinetics and pharmacodynamics of antibiotics, including colistin, are of interest to her.
In addition, Dr. Luisa Sorlí hold a position on a research team. Their research group has dedicated the majority of its focus to investigating the clinical pharmacokinetics of colistin (CMS). The results obtained from their research have significantly influenced the field of clinical practice.
At present, their research also encompasses the examination of the pharmacokinetics of newly developed antibiotics (beta-lactams in combination with beta-lactamase inhibitors) in plasma and the epithelial lung fluid.
Prof. Haibo Qiu (Nanjing, China)
Prof. Haibo Qiu is a Chair Professor and Doctoral Supervisor at Southeast University. He is recognized as an Changjiang Scholar by the Minister of Education a Young or Middle-aged Expert with Outstanding Contribution by the Ministry of Health. Additionally, he has received a special government allowance from the State Council. Prof. Qiu leads the national-level expert medical emergency response team on critical care medicine under the National Health Commission and serves as the third-term Chairman of the Chinese Society of Critical Care Medicine.
He also holds significant roles in various professional organizations, including President-elect of the Chinese Association of Critical Care Physicians, Editor-in-Chief of the Chinese Journal of Critical Care & Intensive Care Medicine, and Principal Scientist of the National Key Research and Development Program of China. Prof. Qiu is a member of the editorial boards for Critical Care Medicine and Annals of Intensive Care, and he is a Fellow of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Additionally, he is a reviewer for the National Natural Science Foundation of China.
Prof. Qiu’s primary research interests are in Acute Respiratory Distress Syndrome (ARDS) and organ failure/functional reconstruction. Prof. Qiu has published over 100 SCI-indexed papers as the first or corresponding author. His work has appeared in prestigious journals, including the New England Journal of Medicine (2 papers), JAMA, Lancet sub-journals (3 papers), Intensive Care Medicine, Critical Care Medicine, and Annals of Intensive Care. His publications have been cited over 16,980 times, and he has an H-index of 50, with 2 highly-cited papers.
Prof. Yonghong Xiao (Hangzhou, China)
Prof. Yonghong Xiao holds the positions of Principal Investigator and Deputy-director at the State Key Laboratory of Diagnosis & Treatment of Infectious Diseases, 1st Affiliated Hospital, School of Medicine, Zhejiang University. His primary interests include infectious diseases, basic and clinical research on antimicrobial agents, surveillance and mechanisms of bacterial resistance, as well as clinical pharmacology and antimicrobial stewardship.
Prof. Xiao founded the MOH National Antimicrobial Resistance Investigation Network and in 2015 conducted the first One-Health AMR containment program in China. He holds multiple positions in domestic and international societies and associations and has authored more than 500 peer-review papers and 30 books and chapters.
Prof. Yi Shi (Nanjing, China)
Prof. Yi Shi is the Chief Physician and Doctoral Supervisor at the Department of Respiratory and Critical Care Medicine, Jinling Hospital, Medical School of Nanjing University. He is a Fellow of the American College of Chest Physicians (FCCP). Prof. Shi holds several significant roles in various committees, including as a standing committee member of the Infectious Diseases Society of China and the Medical Mycology Society of the Chinese Medical Education Association. His expertise lies in lung infections, lung cancer, respiratory and critical care medicine, bronchial asthma, and chronic obstructive pulmonary disease (COPD). In academia, he serves as the Deputy Editor-in-Chief of the Chinese Journal of Infection and Chemotherapy. Prof. Shi has authored 8 monographs and published over 100 papers.
Dr. Yaxin Fan (Shanghai, China)
Dr. Yaxin Fan received her Ph.D. from Fudan University and was a visiting scholar at the University of Manchester. She is currently employed at the Institute of Antibiotics, Huashan Hospital, where she specializes in therapeutic drug monitoring and pharmacokinetic/pharmacodynamic analysis of antimicrobials. She has contributed to the development of concentration determination methods, clinical studies, and quality assessments for many antimicrobials, including colistin methanesulfonate (CMS). Additionally, she has focused on model-informed precision dosing to facilitate personalized dosing regimens for each infected patient.
Prof. Dong Wei (Wuxi, China)
Prof. Dong Wei, MD, is the Deputy Chief Physician at the Transplantation Center and Assistant Director of the Lung Transplant Laboratory at Wuxi People’s Hospital. He is also a visiting scholar at Toronto General Hospital in Canada. Prof. Wei specializes in the clinical treatment of lung transplants and research on lung injury and repair. He has received multiple provincial and ministerial science and technology awards, published over ten papers, and co-authored the Technical specification for diagnosis and treatment of complications and postoperative follow-up after lung transplantation in China (2019 edition).
Prof. Wei holds several academic positions, including committee memberships in the Youth Committee and Committee of Fundamental Research Assembly of the Organ Transplantation Branch of the Chinese Medical Association. He also serves as Deputy Director of the Youth Committee of the Organ Transplantation Branch of the Jiangsu Medical Association and Secretary of Lung Transplantation Assembly of Thoracic Surgery Branch of the Jiangsu Medical Association. Additionally, he is a committee member of the Respiratory Physicians Branch of the Chinese Medical Doctor Association and a youth committee member of Organ Transplantation Branch of the Cross-Strait Medical Exchange Association.
Prof. Bangchuan Hu (Hangzhou, China)
Prof. Bangchuan Hu, MD, is a Chief Physician and Professor, as well as a Master’s Supervisor and Deputy Director of the Department of Critical Care Medicine at Zhejiang Provincial People’s Hospital. He holds several academic positions, including membership in the Intensive Care Medicine Branch of both the Zhejiang Medical Association and Zhejiang Medical Doctor Association. Additionally, he is an active member of the Zhejiang Provincial Association for Intestinal and Parenteral Nutrition. He also serves an associate member and secretary of the Zhejiang Provincial Association for Critical Care Rehabilitation.
Prof. Zhiyong Zong (Chengdu, China)
Dr. Zong is a senior physician-scientist for infectious diseases and oversees the infectious diseases ward in West China Hospital, Sichuan University, Chengdu, China. He served as the International Ambassador of the Society for Healthcare Epidemiology of America in 2011 and was awarded the Newton Advanced Fellowship by the Royal Society, UK. His expertise lies in the management of infections in critically ill or immunocompromised patients caused by multidrug-resistant organisms. His primary research interests include the epidemiology and mechanisms of antimicrobial resistance in Enterobacteriaceae and the prevention and control of multidrug-resistant organisms. He has authored over 200 peer-reviewed papers in journals indexed by the Science Citation Index, such as Lancet Microbe, Clinical Infectious Diseases, Clinical Microbiology Reviews, Trends in Microbiology, and PLoS Medicine.
Prof. Hua Wu (Zhengzhou, China)
Prof. Wu is a Professor in the College of Veterinary Medicine at Henan Agricultural University. Additionally, she holds the positions of Executive Director for both the International Cooperation Industry Technology Innovation Strategic Alliance for Agricultural and Animal Husbandry and the Chinese Herbal Medicine Pharmacology Branch of the Henan Province Association of Animal Husbandry and Veterinary Science.
Her research focusses on veterinary pharmacology, toxicology, and drug safety evaluation, with 45 publications co-authored. Prof. Wu’s research is directed towards understanding the mechanisms of both polymyxin resistance and its reversal, as well as exploring novel applications of polymyxin B in combating multidrug-resistant K. pneumoniae infection. She also investigates potential antibiotic replacement strategies, particularly bacteriophage therapy.
Supported by three NSFC projects, one sub-project of the 13th Five-Year Plan Primary Research and Development Project, and collaborative research projects between universities and enterprises, Prof. Wu leads Critical international Science and Technology Cooperation Projects and Key Science and Technology Research Projects in Henan Province. Serving as one of the Principal Investigators, her team has developed two III-class novel veterinary medicines and obtained six patents for invention.
A/Prof. Jing Lu (Tianjin, China)
A/Prof. Jing Lu is an Associate Investigator at the Tianjin Institute of Infectious Disease, the Second Hospital of Tianjin Medical University, China. After graduating from the Institute of Biophysics, Chinese Academy of Sciences in 2011, she worked in Australia at The University of Queensland, Monash University, and The University of Melbourne before returning to China in 2023. A/Prof. Lu’s research focuses on mechanisms of pandrug-resistant pathogens, drug toxicity, host response pathways, and host-pathogen-drug interactions. Her goal is to identify resistance mechanisms, optimize drug dosages, and develop novel treatments for PDR pathogens to benefit patients.
Prof. Chao Zhuo (Guangzhou, China)
Prof. Chao Zhuo, MD, serves as the Chief Physician and Director of the Department of Infectious Diseases and the Department of Microbiology at the First Affiliated Hospital of Guangzhou Medical University. He actively serves in various committees and societies, including serving as the vice-chairman of the Chinese Society of Bacterial Infection and Resistance and the Antibiotic Resistance Surveillance Network of the Ministry of Health in China. His research interests primarily focus on respiratory tract infections, lung damage, antimicrobial surveillance, and bacterial antimicrobial resistance mechanisms. Prof. Zhuo has published over 50 peer-reviewed papers in esteemed journals such as The Lancet Infectious Diseases, Nature Communications, Clinical Infectious Diseases, Clinical Microbiology and Infection, and Emerging Microbes & Infections. He is the principal investigator of seven National Natural Science Foundation projects.
Prof. Haihui Huang (Shanghai, China)
Prof. Haihui Huang is a Chief Physician, Professor, Doctoral Supervisor, and Deputy Director of the Institute of Antibiotics at Huashan Hospital, Fudan University. Prof. Huang also serves as the Deputy Director of the Key Laboratory of Antibiotic Clinical Pharmacology of the National Health Commission. She is the incoming Chairperson of the Infection and Chemotherapy Branch of the Shanghai Medical Association and leads the Bacterial Infection and Antimicrobial Resistance Prevention and Control Group. Furthermore, Prof. Huang is a member of the Drug Therapy Committee of the Shanghai Pharmaceutical Association and the Secretary of the Committee on Drug Evaluation of the Chinese Pharmaceutical Association.
Prof. Huang has long been dedicated to the clinical diagnosis and treatment of complex and refractory infections caused by drug-resistant bacteria and fungi across various body sites, as well as the diagnosis and management of Fever of Unknown Origin (FUO). She has a particular focus on intractable infections in immunocompromised patients, such as those undergoing liver and kidney transplants. In recent years, she has led over ten international multi-center (China region) and domestic clinical trials for new anti-infective drugs and has participated in the formulation of six guidelines on antibacterial drugs by the Center for Drug Evaluation, NMPA.
Her primary research interests include bacterial resistance mechanisms, infections in immunocompromised populations, and the development and application of new antibacterial drugs. As the principal investigator, she has undertaken three projects funded by the National Natural Science Foundation of China, one sub-project under a Major Program of the Ministry of Science and Technology of China, and six provincial and ministerial-level projects. She has also been selected for the Shanghai Pujiang Talent Program.
Yuan Li (Hengyang, China)
Yuan Li graduated with a Master’s degree in Basic Medicine from University of South China in 2015. Since then, she has served as a clinical pharmacist in the Central Laboratory of the Third Hospital of Changsha. In 2017, Yuan Li was appointed as the Quality Management Director of the Phase I clinical Trial Center.
Yuan Li has been participated in and been responsible for the design and quality management of various clinical trials, including bioequivalence and pharmacokinetic studies, the drug categories involved include anti-infective drugs, cardiovascular drugs, and anti-tumor drugs, among others, administered via inhalation, nasal sprays, and injection. She is dedicated to clinical research and the evaluation of new drugs, as well as the clinical pharmacology of anti-infective drugs.
Prof. Guozhong Lu (Wuxi, China)
Prof. Guozhong Lu, MD, is a Chief Physician and Doctoral Supervisor at Jiangnan University Affiliated Hospital. He serves as the Director of the Burn Treatment Center, the National Emergency Medicine Research Center, the Jiangsu Provincial Burn Treatment Center, the Engineering Technology Center for Burn Recovery and Reconstruction, and the Burn and Trauma Treatment Center of Jiangnan University Affiliated Hospital. Prof. Lu holds several prestigious positions, including Distinguished Expert enjoying Special Government Allowances from the State Council and Visiting Scholar at the Russian Academy of Engineering. He is actively involved in numerous academic societies, serving as the Chairman of the Chinese Burn Surgery Committee and the Burn and Repair Materials branch of the Chinese Society for Biomaterials.
Prof. Lu’s research focuses on the diagnosis and treatment of severe and complicated burn injuries, including post burn scar contracture, restoration of functional abnormalities, acute and chronic wounds, complex and difficult-to-heal wounds, early microplastic surgery for scars, and early anti-scar treatment. He has led over 20 national and provincial-level research projects, including those under the 973 Program and major provincial projects, and has earned more than 20 national and provincial awards, including the First Prize of the State Science and Technology Advancement Award. Prof. Lu has published over 200 SCI-indexed papers and serves as the Editor-in-Chief of Chinese Journal of Disaster Medicine and the Deputy Editor-in-Chief of Chinese Journal of Burns and Wounds.
Prof. Jichang Li (Harbin, China)
Prof. Jichang Li holds positions as a Professor and Doctoral Supervisor in the College of Veterinary Medicine at Northeast Agricultural University. She is recognized as an expert in veterinary drug evaluation by the Ministry of Agriculture and Rural Affairs of the People’s Republic of China. Prof. Li actively contributes to various committees, serving as a member of the 7th Chinese Veterinary Pharmacopoeia Commission and as the Deputy Secretary-General of the Committee of Veterinary Toxicology within the Chinese Society of Toxicology. Furthermore, she holds expertise within the Veterinary Drug Branch of the Pet Medicine Think Tank at the Chinese Veterinary Medicine Association.
Her research focuses on the development and safety evaluation of veterinary drugs, elucidating mechanisms of drug action, and advancing veterinary drug residue detection technology. Prof. Li has led nearly 30 research projects, many of which received funding from the National Natural Science Foundation of China. She has published over 300 academic papers, with over 70 indexed by SCI. Additionally, Prof. Li serves as an editorial board member for Scientia Agricultura Sinica and the Heilongjiang Animal Science and Veterinary Medicine journal. She has received several awards, including the Heilongjiang Province High-Quality Course Award and the Heilongjiang Province Science and Technology Invention Award. Prof. Li innovative work has resulted in the acquisition of seven national invention patents, and she has authored over 10 monographs.
Prof. Yubo Tang (Guangzhou, China)
Prof. Yubo Tang is the Deputy Director of the Pharmacy Department at the First Affiliated Hospital of Sun Yat-sen University and serves as a Master’s Supervisor. She earned her Ph.D. with high honors (Magna Cum Laude) from the University of Duisburg-Essen, Germany, under a full scholarship from the China Scholarship Council. Prof. Tang holds several significant roles in professional committees, including being a member of the Youth Committee of the Hospital Pharmacy Professional Committee of the Chinese Pharmaceutical Association and Deputy Director of the Youth Committee of the Clinical Pharmacy branch of the Guangdong Medical Association. Her research primarily focuses on the practical application of clinical pharmacy within hospital settings. Over the past five years, Prof. Tang has published over 30 SCI-indexed papers, including articles in high-impact journals such as JAMA Oncology. She has also been the principal investigator on several projects funded by the National Natural Science Foundation of China and Guangdong Provincial Science and Technology programs. Additionally, she holds seven national innovation patents and has contributed as editor-in-chief or deputy editor-in-chief to two books.
Prof. Rui Wang (Beijing, China)
Prof. Rui Wang is a Doctoral Supervisor at the Department of Clinical Pharmacology, Chinese People’s Liberation Army General Hospital. Additionally, she serves as the Deputy Director of the Ethics Committee at the Chinese People’s Liberation Army General Hospital and holds several honorary Director and Deputy Director positions in various national committees related to clinical evaluation and infectious diseases. Prof. Wang is an expert member of the New Drug Evaluation Committee for the State and Military, an expert reviewer for the National Natural Science Foundation projects, and a recipient of a special government allowance. She also provides consultation services for the Health Committee of the Central Military Commission. Her editorial roles include Deputy Editor-in-Chief of the Chinese Journal of New Drugs, Chinese Journal of Clinical Pharmacology, and Chinese Journal of New Drugs and Clinical Remedies. She also serves as an editorial board member for over ten statistical source journals.
Prof. Xiaoju Lv (Chengdu, China)
Prof. Xiaoju Lv, MD, holds positions as Chief Physician, Professor, and Doctoral Supervisor at the West China Hospital of Sichuan University, where she also serves as the Director of the Center of Infectious Diseases. She is a standing committee member of the Chinese Society of Bacterial Infection and Resistance and a member of the Committee of the Chinese Society of Infectious Diseases under the Chinese Medical Association. Additionally, Prof. Lv serves as an executive director of the Infectious Diseases Society of China and a standing committee membership in the Critical Care Medicine Branch of the same association. She also contributes as a member to various national committees on infection control and clinical microbiology.
Prof. Lv specializes in diagnosing and treating various infections caused by bacteria, fungi, protozoa, and viruses, affecting systems including intracranial, respiratory, urinary, bloodstream, digestive, and skin/soft tissue, as well as hepatitis and other diseases. She has extensive experience in managing Fever of Unknown Origin (FUO), the rational use of antibiotics, and the diagnosis and treatment of infections caused by drug-resistant bacteria.
Prof. Xuefu You (Beijing, China)
Prof. Xuefu You is a Professor, Doctoral Supervisor, and the Deputy Director of the Institute of Medical Biotechnology at the Chinese Academy of Medical Sciences and Peking Union Medical College. Recognized as a Leading Talent in Technological Innovation within the Ten-Thousands Talents Program and a recipient of special government allowances from the State Council of China, Prof. You has also been honored as an Outstanding Expert by the Ministry of Health. Additionally, he serves as the Director of the Beijing Key Laboratory. Prof. You holds several prominent positions, including Chairman of the Antibiotics Committee of the Chinese Pharmaceutical Association and Vice Chairman of the Chemotherapy Pharmacology Committee of the Chinese Pharmacological Society. His research focuses on the pharmacology of anti-infective drugs.
He has led numerous projects, including those funded by the Major Program of the National Natural Science Foundation of China, major projects under the National 13th Five-Year Plan, key projects under the National 11th and 12th Five-Year Plans, and the CAMS Innovation Fund for Medical Sciences. He has published over 100 papers indexed in SCI in prestigious journals such as Acta Pharmaceutica Sinica B, Signal Transduction and Targeted Therapy, Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy, and JMC. His accolades include the State Science and Technology Advancement Award (Second Prize), the Wu Jieping – Paul Janssen Medical & Pharmaceutical Award in the pharmaceutical field, and the Commemorative Medal for the 70th Anniversary of the Founding of the People’s Republic of China.
Prof. Qi Pei (Changsha, China)
Prof. Qi Pei is a Chief Pharmacist, Doctoral Supervisor, and Postdoctoral Fellow of FDA Quantitative Pharmacology. He currently serves as the Deputy Director of the Department of Pharmacy at the Third Xiangya Hospital of Central South University.
Recognized as a High-Level Talent and Academic Leader in medical disciplines by Hunan Province, Prof. Pei holds several prominent positions, including assessor for the Center for Food and Drug Inspection of CFDA. He is a standing committee member of the Quantitative Pharmacology Committee of the Chinese Pharmacological Society and a youth committee member of the Clinical Pharmacology Monitoring Committee of the Chinese Pharmacological Society. Prof. Pei is an editorial board member and youth editor for several journals, including Anti-Infection Pharmacy, Journal of Chinese Research Hospitals, The Chinese Journal of Clinical Pharmacology, and Chinese Journal of Clinical Pharmacology and Therapeutics.
Prof. Pei’s research interests include therapeutic drug monitoring, model-guided new drug development, and precision medicine. He leads more than ten research projects funded by the National Natural Science Foundation of China, “Significant New Drugs Development” sub-projects, and Natural Science Foundations of Hunan Province. He has published over 30 SCI-indexed papers as the first or corresponding author, holds 3 patents, and has contributed to six books, including three textbooks.
Prof. Pei has received multiple awards, including the First Prize for Scientific and Technological Progress in Hunan Province and the First Prize for Medical Science and Technology in Hunan Province. He is a key member of the development team for the first clinical pharmacological model and statistics cloud platform (CPhaMAS) in China.
Prof. Xin Li (Changsha, China)
Prof. Xin Li, MD, is a Master Supervisor and the Vice Dean of the Third Hospital of Changsha. She concurrently serves as the Director of the Pharmacy Department. She also holds several significant positions, including Director of the Hunan Provincial Key Laboratory of Anti-Resistance Microbial Drugs, Director of the Changsha Anti-Microbial Clinical Application Research Institute, and Director of the Quality Control Center for Pharmaceutical Management in Changsha.
Prof. Li’s main research areas focus on the clinical pharmacology of anti-infective drugs and the clinical research and evaluation of new drugs. She has published over 50 papers in domestic and international professional journals, including 9 SCI-indexed papers, as the first or corresponding author. She has led more than 10 provincial and municipal research projects, holds one China Invention Patent, and three Practical New-type Patents. She has also contributed to four monographs and participated in drafting three industry guidelines and consensus documents.
Prof. Li has been honored with several prestigious titles, including National Outstanding Pharmacist by the Chinese Pharmaceutical Association, Outstanding Pharmacist of Hunan Province, Outstanding Physician of Changsha, Furong Pioneer of Changsha, and Famous Doctor of Changsha.
Prof. Zhihui Hao (Beijing, China)
Prof. Zhihui is the Deputy Director of the National Key Laboratory of Veterinary Public Health Safety and a member of the National Expert Committee on Veterinary Drug Residues and Drug Resistance Control of the Ministry of Agriculture and Rural Affairs. Her research focuses on veterinary public health safety and animal health breeding. She applies plant-derived ingredients and traditional Chinese veterinary medicine to prevent and control bacterial resistance in animal-derived products, thereby ensuring their safety. Building on this foundation, she has developed a series of active substances with synergistic activity that reduced drug resistance in clinical practice. Prof. Zhihui has also developed Chinese-Western combination preparations, new veterinary drugs, feed additives, and disinfectants to combat clinical infections caused by drug-resistant bacteria such as MARS and MCR, thereby facilitating industrial transformation and application. She maintains close partnerships with leading domestic enterprises in animal protection and breeding, providing continuous support to production lines.
Prof. Zhihui is an expert in the New Veterinary Drug Evaluation and Consultation Expert Database, a member of the Veterinary Pharmacopoeia Committee, the GLP/GCP supervision and inspection expert database, and the Chinese herbal medicine expert group. She has been selected for the national High-Level Talent Support Program and appointed as a High-Level Distinguished Professor by the Ministry of Education. Additionally, she has received multiple scientific research awards, including the Second Prize of the National Science and Technology Progress Award.
A/Prof. Hongqiang Qiu (Fuzhou, China)
A/Prof. Hongqiang Qiu obtained a PhD in pharmacology and holds positions as Chief Pharmacist, Associate Professor, and Master’s Supervisor at Fujian Medical University Union Hospital. He is recognized as a High-Level Talent in Fujian Province and a key researcher at the National Drug clinical Trial Registration Institution. A/Prof. Qiu serves as the Deputy Director of the Committee on Pharmaceutical Genetics and Pharmacogenomics of the Fujian Pharmaceutical Association and is a standing committee member of the Committee on Oncology Clinical Pharmacy of the Fujian Anti-Cancer Association. Additionally, he serves on various national and provincial committees on pharmacology.
Dr. Qiu has led and participated in numerous provincial projects and has contributed to National Science and Technology Major Projects, as well as projects funded by the National Natural Science Foundation of China. He has published over 50 papers, including those indexed by SCI. Additionally, he is a youth editorial board member and reviewer for Drug Evaluation Research and a reviewer for the Strait Pharmaceutical Journal. His research focuses on therapeutic drug monitoring, in vivo drug analysis, the pharmacokinetics and pharmacodynamics of antimicrobial agents, analysis of drug resistance, pharmaceutical genomics, human bioavailability and bioequivalence of drugs, and phase I clinical research of innovative drugs.